- All sections
- C - Chemistry; metallurgy
- C07K - Peptides
- C07K 14/71 - Receptors; Cell surface antigens; Cell surface determinants for growth regulators
Patent holdings for IPC class C07K 14/71
Total number of patents in this class: 2076
10-year publication summary
|
122
|
147
|
164
|
177
|
158
|
230
|
249
|
181
|
155
|
9
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Acceleron Pharma Inc. | 373 |
143 |
| Regeneron Pharmaceuticals, Inc. | 3980 |
133 |
| Amgen Inc. | 3900 |
36 |
| Immatics Biotechnologies GmbH | 1170 |
31 |
| The Regents of the University of California | 19503 |
28 |
| Board of Regents, The University of Texas System | 5613 |
24 |
| Keros Therapeutics, Inc. | 61 |
24 |
| Genentech, Inc. | 3867 |
20 |
| City of Hope | 958 |
20 |
| Merck Patent GmbH | 5845 |
19 |
| The Board of Trustees of the Leland Stanford Junior University | 6239 |
18 |
| The Trustees of the University of Pennsylvania | 4254 |
18 |
| Genzyme Corporation | 1211 |
18 |
| The Johns Hopkins University | 5529 |
17 |
| Novartis AG | 11276 |
16 |
| Biocon Limited | 224 |
16 |
| Precigen Inc | 115 |
16 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3352 |
15 |
| National Research Council of Canada | 1566 |
14 |
| Immunitybio, Inc. | 267 |
14 |
| Other owners | 1436 |